Ignite Creation Date:
2025-12-24 @ 7:52 PM
Ignite Modification Date:
2026-01-22 @ 9:28 PM
Study NCT ID:
NCT00660504
Status:
COMPLETED
Last Update Posted:
2014-07-18
First Post:
2008-04-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Sponsor:
Sumitomo Pharma (Suzhou) Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
D0750018
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None